Amendments to the Claims:

This listing of claims replaces all previous versions, and listings, of claims pending in this application:

1-24. (Canceled)

25. (Currently amended) An isolated heteromultimer comprising at least a first polypeptide and a second polypeptide, wherein

1) the first polypeptide is associated with the second polypeptide via an interface, said interface having introduced therein at least one protuberance or cavity such that ~~which meet at an engineered interface, wherein said engineered interface further comprises an interface of the first polypeptide, and an interface of the second polypeptide~~:

(a) the interface of the first polypeptide comprises a protuberance that is positionable in a cavity in the interface of the second polypeptide, or

(b) the interface of the first polypeptide comprises a cavity that accommodates ~~is positionable in~~ a protuberance of the second polypeptide,

~~wherein the protuberance or cavity, or both, have been introduced into the engineered interface~~ such that a greater ratio of heteromultimer:homomultimer forms than for a multimer having a wild-type ~~non-engineered~~ interface, and

2) the first and second polypeptides each comprise an antibody constant domain.

26-27. (Canceled)

28. (Previously presented). A composition comprising the heteromultimer of any of claims 25, 39, 57-59, 66, 75, and 81 and a pharmaceutically acceptable carrier.

29-38. (Canceled)

39 (Previously presented). The heteromultimer of Claim 25 wherein the interface comprises both (a) and (b).

40-41. (Canceled)

42. (Currently amended) The heteromultimer of Claim 25 wherein the protuberance has been introduced into the ~~engineered~~ interface.

43. (Currently amended) The heteromultimer of Claim 25 wherein the cavity has been introduced into the ~~engineered~~ interface.

44 (Previously presented) The heteromultimer of Claim 42, wherein protuberance comprises a non-naturally occurring amino acid residue.

45. (Previously presented) The heteromultimer of Claim 42, wherein the protuberance comprises a naturally occurring amino acid residue.

46. (Previously presented) The heteromultimer of Claim 45, wherein the protuberance comprises an arginine (R) residue.

47. (Previously presented) The heteromultimer of Claim 45, wherein the protuberance comprises a phenylalanine (F) residue.

48 (Previously presented). The heteromultimer of Claim 45, wherein the protuberance comprises a tyrosine (Y) residue.

49 (Previously presented). The heteromultimer of Claim 45, wherein the protuberance comprises a tryptophan (W) residue.

50 (Previously presented). The heteromultimer of Claim 42, wherein the cavity comprises a non-naturally occurring amino acid residue.

51 (Previously presented). The heteromultimer of Claim 42, wherein the cavity comprises a naturally occurring amino acid residue.

52 (Previously presented). The heteromultimer of Claim 51, wherein the cavity comprises an alanine (A) residue.

53 (Previously presented). The heteromultimer of Claim 51, wherein the cavity comprises a serine (S) residue.

54 (Previously presented). The heteromultimer of Claim 51, wherein the cavity comprises a threonine (T) residue.

55 (Previously presented). The heteromultimer of Claim 51, wherein the cavity comprises a valine (V) residue.

56. (Canceled)

57. (Currently amended) The heteromultimer of Claim 25, wherein the antibody constant domain ~~engineered interface~~ comprises an immunoglobulin constant domain.

58 (Previously presented). The heteromultimer of Claim 57, wherein the immunoglobulin constant domain is a CH3 domain.

59 (Previously presented). The heteromultimer of Claim 58, wherein the CH3 domain is from an IgG.

60 (Previously presented). The heteromultimer of Claim 59, wherein the IgG is of the IgG1 subtype.

61 (Previously presented). The heteromultimer of Claim 59, wherein the IgG is of the IgG2 subtype.

62 (Previously presented). The heteromultimer of Claim 59, wherein the IgG is of the IgG2A subtype.

63 (Previously presented). The heteromultimer of Claim 59, wherein the IgG is of the IgG2B subtype.

64 (Previously presented). The heteromultimer of Claim 59, wherein the IgG is of the IgG3 subtype.

65 (Previously presented). The heteromultimer of Claim 59, wherein the IgG is of the IgG4 subtype.

66 (Previously presented). The heteromultimer of Claim 25, wherein the first or second polypeptide further comprises a binding domain.

67 (Previously presented). The heteromultimer of Claim 66, wherein the binding domain is an antigen binding domain.

68 (Previously presented). The heteromultimer of Claim 66, wherein the binding domain is a ligand binding domain.

69 (Previously presented). The heteromultimer of Claim 66, wherein the binding domain is a receptor binding domain.

70 (Previously presented). The heteromultimer of Claim 66, wherein the binding domain is an enzymatic domain.

71 (Previously presented). The heteromultimer of Claim 66, wherein the binding domain is an antibody variable domain.

72 (Previously presented). The heteromultimer of Claim 25 which is a multi-specific antibody.

73 (Previously presented). The heteromultimer of Claim 72 which is a bi-specific antibody.

74 (Previously presented). The heteromultimer of Claim 72 which is a tri-specific antibody.

75 (Previously presented). The heteromultimer of Claim 25 which is an immunoadhesin.

76 (Previously presented). The heteromultimer of Claim 75 which is a multi-specific immunoadhesin.

77 (Previously presented). The heteromultimer of Claim 76 which is a bi-specific immunoadhesin.

78 (Previously presented). The heteromultimer of Claim 76 which is a heterodimer.

79 (Previously presented). The heteromultimer of Claim 76 which is a heterotrimer.

80 (Previously presented). The heteromultimer of Claim 76 which is a heterotetramer.

81 (Previously presented). The heteromultimer of Claim 25 which is an antibody-immunoadhesin chimera.